CA2382850A1 - Novel inhibitors of the integrin .alpha.v.beta.3 - Google Patents
Novel inhibitors of the integrin .alpha.v.beta.3 Download PDFInfo
- Publication number
- CA2382850A1 CA2382850A1 CA002382850A CA2382850A CA2382850A1 CA 2382850 A1 CA2382850 A1 CA 2382850A1 CA 002382850 A CA002382850 A CA 002382850A CA 2382850 A CA2382850 A CA 2382850A CA 2382850 A1 CA2382850 A1 CA 2382850A1
- Authority
- CA
- Canada
- Prior art keywords
- phenyl
- ylamino
- compounds
- acid
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19939981.6 | 1999-08-24 | ||
DE19939981A DE19939981A1 (de) | 1999-08-24 | 1999-08-24 | Neue Inhibitoren des Integrins alphavß3 |
PCT/EP2000/007591 WO2001014338A1 (de) | 1999-08-24 | 2000-08-04 | NEUE INHIBITOREN DES INTEGRINS αVβ¿3? |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2382850A1 true CA2382850A1 (en) | 2001-03-01 |
Family
ID=7919343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002382850A Abandoned CA2382850A1 (en) | 1999-08-24 | 2000-08-04 | Novel inhibitors of the integrin .alpha.v.beta.3 |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP1206454A1 (es) |
JP (1) | JP2003507458A (es) |
KR (1) | KR20020016651A (es) |
CN (1) | CN1370147A (es) |
AU (1) | AU6570500A (es) |
BR (1) | BR0013504A (es) |
CA (1) | CA2382850A1 (es) |
CZ (1) | CZ2002523A3 (es) |
DE (1) | DE19939981A1 (es) |
HK (1) | HK1049666A1 (es) |
HU (1) | HUP0203697A3 (es) |
MX (1) | MXPA02001861A (es) |
NO (1) | NO20020886L (es) |
PL (1) | PL352989A1 (es) |
SK (1) | SK2282002A3 (es) |
WO (1) | WO2001014338A1 (es) |
ZA (1) | ZA200202287B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001269821A1 (en) | 2000-06-15 | 2001-12-24 | Barbara Chen | Cycloalkyl alkanoic acids as integrin receptor antagonists |
US6531494B1 (en) | 2001-08-29 | 2003-03-11 | Pharmacia Corporation | Gem-substituted αvβ3 antagonists |
ES2436170T3 (es) * | 2003-12-03 | 2013-12-27 | The Scripps Research Institute | Anticuerpos y péptidos específicos de la integrina alfa II beta3 |
EP1802618A1 (en) * | 2004-10-14 | 2007-07-04 | Pharmacia Corporation | Biphenyl integrin antagonists |
HUE053620T2 (hu) * | 2016-11-08 | 2021-07-28 | Bristol Myers Squibb Co | Pirrol amidok mint alfa-V integrin inhibitorok |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08325264A (ja) * | 1995-05-31 | 1996-12-10 | Sumitomo Metal Ind Ltd | 新規2−芳香環置換−3−フェニルプロピオン酸またはアクリル酸誘導体 |
AU717283B2 (en) * | 1996-10-30 | 2000-03-23 | Merck & Co., Inc. | Integrin antagonists |
CN1299282A (zh) * | 1998-03-10 | 2001-06-13 | 史密丝克莱恩比彻姆公司 | 玻连蛋白受体拮抗剂 |
-
1999
- 1999-08-24 DE DE19939981A patent/DE19939981A1/de not_active Withdrawn
-
2000
- 2000-08-04 MX MXPA02001861A patent/MXPA02001861A/es unknown
- 2000-08-04 HU HU0203697A patent/HUP0203697A3/hu unknown
- 2000-08-04 EP EP00953158A patent/EP1206454A1/de not_active Withdrawn
- 2000-08-04 KR KR1020027001419A patent/KR20020016651A/ko not_active Application Discontinuation
- 2000-08-04 PL PL00352989A patent/PL352989A1/xx unknown
- 2000-08-04 WO PCT/EP2000/007591 patent/WO2001014338A1/de not_active Application Discontinuation
- 2000-08-04 CN CN00811950A patent/CN1370147A/zh active Pending
- 2000-08-04 CZ CZ2002523A patent/CZ2002523A3/cs unknown
- 2000-08-04 AU AU65705/00A patent/AU6570500A/en not_active Abandoned
- 2000-08-04 BR BR0013504-6A patent/BR0013504A/pt not_active IP Right Cessation
- 2000-08-04 SK SK228-2002A patent/SK2282002A3/sk unknown
- 2000-08-04 CA CA002382850A patent/CA2382850A1/en not_active Abandoned
- 2000-08-04 JP JP2001518427A patent/JP2003507458A/ja active Pending
-
2002
- 2002-02-22 NO NO20020886A patent/NO20020886L/no not_active Application Discontinuation
- 2002-03-20 ZA ZA200202287A patent/ZA200202287B/en unknown
-
2003
- 2003-03-12 HK HK03101785.4A patent/HK1049666A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
AU6570500A (en) | 2001-03-19 |
SK2282002A3 (en) | 2002-06-04 |
KR20020016651A (ko) | 2002-03-04 |
WO2001014338A1 (de) | 2001-03-01 |
CZ2002523A3 (cs) | 2002-05-15 |
DE19939981A1 (de) | 2001-03-01 |
NO20020886D0 (no) | 2002-02-22 |
PL352989A1 (en) | 2003-09-22 |
HUP0203697A3 (en) | 2004-04-28 |
CN1370147A (zh) | 2002-09-18 |
BR0013504A (pt) | 2002-05-07 |
JP2003507458A (ja) | 2003-02-25 |
NO20020886L (no) | 2002-02-22 |
ZA200202287B (en) | 2003-08-27 |
MXPA02001861A (es) | 2004-09-06 |
EP1206454A1 (de) | 2002-05-22 |
HK1049666A1 (zh) | 2003-05-23 |
HUP0203697A2 (hu) | 2003-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7632951B2 (en) | Inhibitors of integrin ανβ6 | |
US6559144B2 (en) | Bicyclic amino acids | |
US6743810B2 (en) | Indol-3-yl derivatives | |
US6849646B1 (en) | Chromenone and chromanone derivatives as integrin inhibitors | |
US7135587B2 (en) | Urea and urethane derivatives as integrin inhibitors | |
US6645991B1 (en) | αvβ3 integrin inhibitors | |
CA2382850A1 (en) | Novel inhibitors of the integrin .alpha.v.beta.3 | |
US6521646B1 (en) | Dibenzoazulene derivatives for treating thrombosis, osteoporosis, arteriosclerosis | |
CA2380981A1 (en) | Fluorene derivatives | |
US20040157902A1 (en) | Integrin antagonists | |
US20030187289A1 (en) | Biphenyl derivatives and the use thereof as integrin inhibitors | |
Schadt et al. | Inhibitors of integrin α ν β 6 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |